Vanta Bioscience (BOM:540729) EPS (Basic): ₹0.15 (TTM As of Mar. 2026)


BOM:540729 Vanta Bioscience Ltd BOM:540729
50 GF Score
Price ₹25.35
GF Value ₹12.15
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Vanta Bioscience EPS (Basic)?

Vanta Bioscience BOM:540729 50 EPS (Basic) is ₹0.15 as of Mar. 2026. GuruFocus rates BOM:540729 with a GF Score™ of 50/100 and a GF Value™ of ₹12.15 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Vanta Bioscience's basic earnings per share (Basic EPS) for the six months ended in Mar. 2026 was ₹2.71. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.15.

Vanta Bioscience's EPS (Diluted) for the six months ended in Mar. 2026 was ₹2.71. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.15.

Vanta Bioscience's EPS without NRI for the six months ended in Mar. 2026 was ₹2.71. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.15.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Vanta Bioscience  (BOM:540729) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Vanta Bioscience EPS (Basic) Related Terms

Vanta Bioscience EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Vanta Bioscience's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanta Bioscience EPS (Basic) Chart

Vanta Bioscience Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 -10.27 -3.67 -4.23 0.15

Vanta Bioscience Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 -3.28 -2.18 -2.56 2.71
BOM:540729
50GF Score
Vanta Bioscience Ltd BOM:540729
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanta Bioscience EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Vanta Bioscience's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1.083-0)/7.220
=0.15

Vanta Bioscience's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(19.272-0)/7.111
=2.71

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹0.15 mean?
Vanta Bioscience (BOM:540729) has a EPS (Basic) of ₹0.15 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Vanta Bioscience and its competitors.
Is Vanta Bioscience's EPS (Basic) too high?
Vanta Bioscience's current EPS (Basic) is ₹0.15. Overall, Vanta Bioscience has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's EPS (Basic) compare to TMO and DHR?
Vanta Bioscience's EPS (Basic) of ₹0.15 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Vanta Bioscience and its competitors. Vanta Bioscience's current EPS (Basic) is ₹0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.15, compared to a current price of ₹25.35 — trading 108.6% above its estimated fair value. The current EPS (Basic) is ₹0.15. Vanta Bioscience's overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current EPS (Basic) is ₹0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanta Bioscience (BOM:540729) Overvalued in 2026?

Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued. The current stock price of ₹25.35 is trading 108.6% above its estimated GF Value™ of ₹12.15. GuruFocus considers Vanta Bioscience to be Significantly Overvalued.

Key valuation signals for BOM:540729:

  • EPS (Basic): ₹0.15
  • GF Value™: ₹12.15 vs. price of ₹25.35 (108.6% above fair value)
  • GF Score™: 50/100 with 10 warning signs

No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanta Bioscience Business Description

Address No. 02/G/308/G, Umajay Complex, No. 3/FF/SF/1-20-248, Rasoolpura, Secunderabad, TG, IND, 500003
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
50GF Score

Get the complete analysis for BOM:540729

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹25.35
Price
₹12.15
GF Value